LECT2, A Novel and Direct Biomarker of Liver Fibrosis in Patients With CHB

Chronic hepatitis B (CHB) patients with severe liver fibrosis would be more likely to progress to a poorer prognosis. Treatment is considered once the liver fibrosis reaches significant liver fibrosis (≥S2). Leukocyte cell-derived chemotaxin-2 (LECT2) has been shown to contribute to liver fibrosis p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Honghai, Li, Xutong, Wu, Zihao, Zhao, Linyan, Shen, Jiapei, Liu, Jiaying, Qin, Jiangfeng, Shen, Yuanlong, Ke, Jing, Wei, Yuanyuan, Li, Jiabin, Gao, Yufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492992/
https://www.ncbi.nlm.nih.gov/pubmed/34631799
http://dx.doi.org/10.3389/fmolb.2021.749648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492992/
https://www.ncbi.nlm.nih.gov/pubmed/34631799
http://dx.doi.org/10.3389/fmolb.2021.749648

Ejemplares similares